RYTM
RHYTHM PHARMACEUTICALS, INC.
Nasdaq: RYTM · Boston, MA · Healthcare
$84.92-2.80 (-3.19%)Closed
Market Cap$5.71B
Cash$54.3Mmost recent
Runway4 mo$40.4M Q burn
P/E (TTM)—EPS $-3.11
52-Wk Range$56.79 – $117.62
Avg Volume732.4K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$84.92+117.7%
Pipeline
Drug candidates sponsored by RHYTHM PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Setmelanotide | Healthy+24 more | Recruiting | 2026-10-31 | 19 | |
| Phase 3 | Setmelanotide 2 mg | Bardet-Biedl Syndrome+1 more | Completed | 2023-10-19past | 1 | |
| Phase 2 | LB54640 | Hypothalamic Obesity | Completed | 2026-02-09past | 1 | |
| Phase 1 | Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) | Hypothalamic Obesity+2 more | Recruiting | 2027-11-01 | 1 | |
| Phase 2 | Bivamelagon | Hypothalamic Obesity | Enrolling | 2028-04-15 | 1 | |
| Phase 1 | RM-493 | Overweight+1 more | Completed | 2014-01past | 1 | |
| Phase 1 | Placebo | Obesity+1 more | Completed | 2014-03past | 1 | |
| N/A | Unnamed | Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations | Completed | 2020-06-09past | 1 | |
| N/A | Unnamed | Genetic Forms of Extreme Obesity | Completed | 2020-12-01past | 1 | |
| N/A | Unnamed | POMC Deficiency Obesity+2 more | Completed | 2021-01-22past | 1 | |
| N/A | Setmelanotide, administered subcutaneously [SC], once daily. | Bardet-Biedl Syndrome (BBS)+1 more | Approved For Marketing | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for RYTM. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.